KR20230019512A - Pharmaceutical composition for preventing or treating metabolic disease and skin disease - Google Patents

Abstract

Disclosed in the present invention is a pharmaceutical composition capable of preventing or treating hyperlipidemia, obesity, or skin disease without side effects by using hydrogen stored in a metal compound. The pharmaceutical composition for preventing or treating metabolic disease or skin disease according to the present invention includes a metal compound; and hydrogen intercalated in the metal compound, wherein the metal compound includes a metal particle on which a coating film is formed, and a metal particle or an anion-coupled metal particle, and the skin disease is at least one of atopy, psoriasis, and eczema.

Description

Metabolic disease, pharmaceutical composition for preventing or treating skin disease

The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases and skin diseases containing hydrogen occluded in metal compounds.

As hydrogen has been found to have anti-inflammatory and anti-allergic effects and anti-aging effects such as reducing skin wrinkles, studies on health promotion and treatment and prevention effects of various diseases are being conducted.

Water, beverages, or cosmetics in which molecular hydrogen is dissolved are mainly commercially available and widely used. However, a solution in which hydrogen is dissolved is inconvenient to transport, and when a large amount of hydrogen is generated, there is a safety risk of combustion and explosion.

In addition, hydrogen-containing lotion applied to the skin is difficult to absorb or penetrate into the skin because hydrogen is emitted into the air, and it is difficult to retain it in the lotion for a long time.

Therefore, there is a need for research on hydrogen-containing compositions that can be used for the prevention or treatment of skin diseases.

An object of the present invention is to provide a pharmaceutical composition that can be used for the prevention or treatment of metabolic diseases and skin diseases.

Another object of the present invention is to provide a pharmaceutical composition that can be used for oral or parenteral purposes.

It is also an object of the present invention to provide a pharmaceutical composition with a high hydrogen content.

The objects of the present invention are not limited to the above-mentioned objects, and other objects and advantages of the present invention not mentioned above can be understood by the following description and will be more clearly understood by the examples of the present invention. It will also be readily apparent that the objects and advantages of the present invention may be realized by means of the instrumentalities and combinations indicated in the claims.

Metabolic disease according to the present invention, a pharmaceutical composition for the prevention or treatment of skin disease, a metal compound; and hydrogen intercalated in the metal compound, wherein the metal compound includes a metal particle having a coating film formed thereon, a metal particle or an anion-coupled metal particle, and the skin disease is at least one of atopy, psoriasis, and eczema am.

The pharmaceutical composition for the prevention or treatment of the skin disease is at least one of angelica, japonica, cnidium, sewage, aubergris, mulberry leaf, licorice, golden, yellow lotus, yellow white, gardenia, yeonkyo, gosam, astragalus, peppermint, yongnoe and peony Herbal medicines may be further included.

The metal may include magnesium.

The dissolved concentration of hydrogen may be 0.01 to 30 ppm (v/v).

The coating film may include one or more of vegetable waxes, vegetable oils, and biodegradable polymers.

The pharmaceutical composition according to the present invention can exhibit effects in preventing or treating metabolic diseases and skin diseases without side effects by using hydrogen stored in metal compounds.

In addition to the effects described above, specific effects of the present invention will be described together while explaining specific details for carrying out the present invention.

1 and 2 are photographs showing skin conditions before (left) and after (right) application of the composition according to the present invention to a skin disease area.
Figure 3 shows the results showing the itching improvement (a), erythema improvement (b), inflammation improvement (c), and healer satisfaction (d) after applying the composition according to the present invention to the skin.
Figure 4 is a result showing pore size reduction (a), elasticity improvement (b), skin roughness improvement (c), and wrinkle improvement (d) after applying the composition according to the present invention to the skin.
5 is a result showing the weight gain inhibitory effect after oral administration of the composition according to the present invention to rats.
6 and 7 are toxicity test results showing the safety after long-term oral administration of the composition according to the present invention to rats.

The above objects, features and advantages will be described later in detail with reference to the accompanying drawings, and accordingly, those skilled in the art to which the present invention belongs will be able to easily implement the technical spirit of the present invention. In describing the present invention, if it is determined that the detailed description of the known technology related to the present invention may unnecessarily obscure the subject matter of the present invention, the detailed description will be omitted. Hereinafter, preferred embodiments according to the present invention will be described in detail with reference to the accompanying drawings. In the drawings, the same reference numerals are used to indicate the same or similar components.

Hereinafter, the arrangement of an arbitrary element on the "upper (or lower)" or "upper (or lower)" of a component means that an arbitrary element is placed in contact with the upper (or lower) surface of the component. In addition, it may mean that other components may be interposed between the component and any component disposed on (or under) the component.

In addition, when a component is described as "connected", "coupled" or "connected" to another component, the components may be directly connected or connected to each other, but other components may be "interposed" between each component. ", or each component may be "connected", "coupled" or "connected" through other components.

Hereinafter, a pharmaceutical composition for preventing or treating metabolic diseases and skin diseases according to some embodiments of the present invention will be described.

In the present invention, based on the results of previous clinical studies on the improvement of skin diseases with hydrogen, in order to generate hydrogen that has an effective antioxidant effect in the body, the principle of generating hydrogen gas by mixing organic acid or / and inorganic acid with metal magnesium was applied. .

It is the principle that metal magnesium and organic acid or/and inorganic acid react to generate hydrogen gas, and the amount of hydrogen gas generated during the reaction varies slightly depending on the type of acid.

In addition, there may be a difference in the amount of hydrogen gas generated depending on the acidity, but since it takes a lot of time to ionize in a weak acid, the maximum amount of hydrogen gas can be maintained in the composition by slowly generating hydrogen gas using a weak acid. .

"Occupation" referred to in the present invention means a phenomenon in which hydrogen is absorbed into or on the surface of a metal.

"Hydrogen gas" or "hydrogen" referred to in the present invention means a combination of molecular and atomic hydrogen. In addition, "hydrogen" included in the composition of the present invention includes not only occluded hydrogen, but also hydrogen present on the metal surface and hydrogen present in the composition.

Metabolic diseases referred to in the present invention refer to diseases caused by abnormal metabolic processes. It can be caused by congenital abnormalities of enzymes, acquired diseases of endocrine organs, or malfunctions of organs such as the liver that play an important role in metabolism.

These metabolic diseases may include hypertension, hyperlipidemia, diabetes, and the like.

Hyperlipidemia referred to in the present invention refers to a state in which the amount of fat in the blood is increased due to poor fat metabolism. Hyperlipidemia refers to a disease in which cholesterol in the blood increases, and in a similar term, an abnormal blood lipid state is also referred to as dyslipidemia.

Obesity referred to in the present invention refers to a state with excessive body fat, and the degree of obesity is calculated by body mass index (BMI). According to the criteria, a BMI of 25 or higher is defined as obesity.

Atopy (atopic dermatitis) referred to in the present invention refers to dermatitis accompanied by pruritus (itching), dry skin, and characteristic eczema as a chronic and recurrent inflammatory skin disease that begins mainly in infancy or childhood. In the early stages, blisters, papules, erythema, and edema are mainly observed along with itching, and in the chronic stage, swelling and blisters decrease, but skin wrinkles become prominent or the skin becomes thicker, such as lichenification, scales, and pigmentation.

"Psoriasis" is a chronic inflammatory skin disease in which red papules or plaque-like rashes of various sizes, covered with silvery white scales, with distinct borders, occur repeatedly on the skin of the body. proliferation and inflammation of the dermis.

"Eczema" is a general term for a group of skin diseases that show common clinical and histological characteristics. It is a group of skin diseases that clinically show itching, erythema, scales, clustered papules, and blisters, and histologically, it is superficial dermatitis accompanied by spongyization in the epidermis and an inflammatory skin reaction in which inflammatory cells infiltrate around blood vessels in the dermis. collectively

In general, atopic dermatitis and eczema are used synonymously, but dermatitis is a term referring to all inflammations, and dermatitis has a broader meaning than eczema in strict definition.

In the present invention, the term "prevention" means any action to suppress or delay the onset of skin diseases by administering the composition.

In the present invention, the term "treatment" refers to all activities that improve or beneficially change symptoms caused by skin diseases by administering the composition.

The pharmaceutical composition for preventing or treating metabolic diseases or skin diseases of the present invention includes a metal compound and hydrogen occluded in the metal compound.

The metal compound includes metal particles on which a coating film is formed, metal particles or/and metal particles to which anions are bonded. That is, the metal compound includes metal particles on which a coating film is formed, and includes metal particles or/and metal particles to which anions are bonded. In addition, the metal compound may also include metal particles in which a coating film and anions are bonded together on the surface.

The skin disease may include one or more of atopy, psoriasis and eczema.

The metal may include magnesium. Magnesium is only partially ionized in water, so when magnesium reacts with acid, the reaction is not as violent as other alkali metals, so it has excellent stability. In addition, even if magnesium that does not participate in the reaction with acid remains in water, it does not change to a strong alkali of pH 11 or higher, so there is an advantage that it can be used inside the human body or on the skin.

The composition of the present invention includes hydrogen generated while mixing the metal particles and the acid compound, and the dissolved concentration of hydrogen may be 0.01 to 30 ppm (v/v). Preferably it may be 0.01 ~ 10ppm.

When the dissolved concentration of hydrogen satisfies 0.01 to 30 ppm (v/v), it is possible to suppress weight gain in vivo and improve skin diseases.

The coating film may include one or more of vegetable waxes, vegetable oils, and biodegradable polymers.

Vegetable wax is derived from plants and exists as a solid at room temperature, but becomes a liquid with increased fluidity when heated and can be coated on the surface of metal particles.

The vegetable wax may include at least one of shea butter, cocoa butter, coconut oil, bayberry wax, candelilla wax, carnauba wax, castor wax, esparto wax, and oururi curry wax.

Vegetable oils may be used without particular limitation as long as they are harmless to the living body. For example, vegetable oil is a component extracted from flowers, leaves, seeds, fruits, peels, roots, etc., and it is preferable to use vegetable oils that do not irritate the skin. In particular, among vegetable oils, olive oil, castor oil, avocado oil, and almond oil are used. , Apricot seed oil, malt oil, evening primrose oil, jojoba oil, rosehip oil, palm oil, and macadamia nut oil.

Olive oil is extracted from olive fruit and has excellent solubility in water. Olive oil is mostly oleic acid, and is effective in suppressing moisture evaporation and improving texture, and has relatively good absorption among vegetable oils.

Pimiza oil is extracted from pimija, which refers to castor bean, which has been used as hair oil in Korea since ancient times, and has the property of mixing well with pigments. Pimiza oil contains a lot of ricinol, and has high hydrophilicity and high viscosity.

Jojoba oil is an oil extracted from the jojoba tree, and its main component is an ester of higher unsaturated fatty acids, so it has excellent adhesion and stability to the skin.

Avocado oil is an oil extracted from the fruit of avocado and is particularly effective for dry skin because it contains vitamins. Its composition is oleic acid and linoleic acid, which are known to have excellent penetrability and emollient effects, and are particularly skin-friendly. It is oil.

Apricot seed oil is extracted from apricot seeds and is used as an emollient because of its excellent texture. Malt milk is extracted from the germ of wheat and is known to have antioxidant properties because it contains vitamin E and helps blood circulation.

Evening primrose oil is extracted from the seeds of evening primrose and contains abundant essential fatty acids.

Rosehip oil is extracted from the ovary of wild rose and is known to be effective in healing wounds, and its main components are linolenic acid and ricinoleic acid.

Macadamia nut oil is extracted from the fruits of macadamia nuts and is

Its fatty acid composition is similar to human sebum, and it has good skin affinity and excellent texture.

Biodegradable polymers include polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), poly(L-lactic acid)PLA, polyglycolic acid (PGA) and polylactic acid-glycolic acid. One or more of copolymers (poly(lactic-co-glycolic acid), PLGA) may be included. The polyvinylpyrrolidone and polyethylene glycol are also used as plasma substitutes.

The composition of the present invention may include 0.1 to 100 g of metal particles having a coating film, and 0.1 to 100 g of metal particles or metal particles bonded to anions, but is not limited thereto. The content of the metal particles in the composition of the present invention is not an important factor and can be adjusted according to the subject and symptom to be administered.

The anion is formic acid, acetic acid, propionic acid, methanic acid (formic acid), ethanoic acid (acetic acid), propanoic acid (propionic acid), butanoic acid (butyric acid), n-butyric acid, isobutyric acid, pentanoic acid (valeric acid), n- valeric acid, isovaleric acid, 2-methylbutyric acid, pivalic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, hydroxyacetic acid (glycolic acid), hydroxypropionic acid (lactic acid); D-lactic acid, L-lactic acid, beta-hydroxypropionic acid, alpha-hydroxyvaleric acid, beta-hydroxyvaleric acid, gamma-hydroxyvaleric acid, hydroxymalonic acid (tartronic acid); D-hydroxysuccinic acid, L-hydroxysuccinic acid, dihydroxysuccinic acid (tartaric acid), propenoic acid (acrylic acid), fumaric acid, maleic acid, citric acid, mesoxalic acid, acetone dicarboxylic acid, oxaloacetic acid, aconitinic acid, It may contain an anion of at least one acid compound of tricarbaliic acid and ascorbic acid.

The concentration of these anions in the composition of the present invention may be 0.01 ~ 100ppm (v / v), but is not limited thereto. The concentration of anions in the composition of the present invention is not an important factor and can be adjusted according to the subject and symptoms to be administered.

The pharmaceutical composition for prevention or treatment of the present invention is one or more herbal medicines selected from angelica, japonica, cnidium, hasuo, arquid, mulberry leaf, licorice, golden, yellow lotus, yellow white, gardenia, yeongyo, gosam, astragalus, peppermint, yongnoe and peony may further include.

At this time, further including the herbal medicine means that the extract of the herbal medicine may also be included. Extract refers to an active ingredient separated from a natural product, and refers to a material separated from herbal medicines. Extracts of herbal medicines can be obtained by various known methods.

The composition of the present invention can adjust the content of herbal medicines according to the formulation and purpose. For example, the composition of the present invention may further include 0.001 to 100 g of herbal medicine per 1 g of metal particles, but is not limited thereto. The content of herbal medicines in the composition of the present invention is not an important factor and can be adjusted according to the subject and symptoms to be administered.

Angelica is the root of Seunggeomcho, a perennial plant of the Sanhyeongaceae family. It mainly has anti-inflammatory and analgesic effects. Dong Quai contains nodakenin, decursin, and decursinol.

Ilcheongung is a perennial plant of the mountain type family, and is also called Cheongung (川芎), Gungungi, and Wacheongung by other names. It is effective for pain relief, antispasmodic, bubble, and blood.

Cnidium contains betasitosterol, oleanolic acid, and ferulic acid.

Sewage is native to China and is cultivated as a medicinal plant. The reddish-brown tuberous root is called Shouo in oriental medicine and is used as a tonic, tonic, and laxative. The leaves are used as herbs, and the raw leaves are attached to the infected area to absorb the pus.

Sewage contains eponin, lecithin, and emodin.

Arborvitae (側柏葉) means the leaves of Arborvitae, and in Korea, it refers to the young branches and leaves of Arborvitae. Arborvitae is also called Arborvitae. Arborvitae is used for nosebleeds, hematemesis, alteration of blood, urinary bleeding, and uterine bleeding by lowering blood heat, and is used for seawater, asthma, phlegm, hair loss, seborrheic dermatitis, and traumatic bleeding. It has been reported that it has pharmacological actions such as shortening of bleeding time, antitussive, expectorant action, lowering of blood pressure, antibacterial action, seawater and asthma.

Arborvitae contains myricetin, tannin, and flavonoids.

Mulberry leaves are called Sangyeop (桑葉). The upper leaf is used for fever, headache, eye congestion, seawater, dry mouth, skin hives, etc. This medicine is sweet and bitter in taste and cold in nature. As for the pharmacological action, antidiabetic action, inhibitory action against typhoid bacillus, staphylococcus, etc. have been reported.

Mulberry leaves contain protein, amino acid, and cellulose, fibrin.

Licorice is a medicinal plant, and its roots are reddish brown and go deep into the ground, and its stems are angular and grow straight about 1m. In addition, white hairs grow densely, so it looks grayish white, and the glandular dots are scattered. The flowers bloom in July-August, are 1.4-2.5 cm long, purple, and the roots are sweet, so they are used as sweeteners and herbal medicines.

Licorice contains glycyrrhizin, cysteine, and flavonoids.

Peony is a general term for perennial plants of the Buttercup family, and is cultivated for ornamental purposes in gardens because of its large and beautiful flowers. There are white peony, mountain peony, red peony, and big peony. It is bitter and sour in taste and slightly cold in nature. It has a blood-purifying effect and removes blood, so it is used for fever, hematemesis, epilepsy, and bruises.

Peony contains gallotanin, betasitosterol, and paeoniflorin.

The composition of the present invention may be in various oral or parenteral dosage forms. When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in one or more compounds, for example, starch, calcium carbonate, sucrose or lactose ( lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.

Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is.

Preparations for parenteral administration may include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base material for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin and the like may be used.

The composition of the present invention may be used in oral preparations such as tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, and syrups; And as a sterilized injection solution, it can be suitably formulated and used in the form of parenteral administration such as aqueous solution, non-aqueous solution, suspension, emulsion, freeze-dried preparation, and suppository.

The administration route of the composition of the present invention may be administered through any general route as long as it can reach the target tissue. The composition of the present invention may be administered intramuscularly, intrauterinely, intrathecally, subcutaneously, intradermally, orally, intranasally, or intrarectally, as desired, but is not limited thereto. In addition, the composition may be administered by any device capable of transporting an active substance to a target cell.

The composition of the present invention can be administered in a pharmaceutically effective amount.

In the present invention, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is based on the type and severity of the subject, age, sex, and type of infected virus , activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field.

For example, the daily dose may be 0.1 to 500 mg/day, preferably 0.1 to 200 mg/day, but is not limited thereto.

The daily effective amount and daily intake may also be 0.1 to 500 mg/day, preferably 0.1 to 200 mg/day, but are not limited thereto.

The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And it can be single or multiple administrations. It is important to administer the amount that can obtain the maximum effect with the minimum amount without side effects in consideration of all the above factors, and can be easily determined by those skilled in the art.

The composition of the present invention can be used alone or in combination with methods using surgery, hormone therapy, drug therapy, and biological response modifiers for the prevention or treatment of metabolic diseases and skin diseases.

The method for preparing a pharmaceutical composition for preventing or treating metabolic diseases and skin diseases of the present invention is described as follows.

The method for preparing a pharmaceutical composition for preventing or treating metabolic diseases or skin diseases of the present invention comprises the steps of grinding metal, forming a coating film on the pulverized metal particles, and the metal particles and metal particles having the coating film formed thereon, and an acid compound. It includes the step of preparing an antioxidant composition by mixing.

And the composition of the present invention includes hydrogen generated during mixing of the metal particles and the acid compound.

The grinding of the metal may include cooling the metal at -190°C to -210°C, and grinding the cooled metal to a size of 0.1 to 50 μm in an inert gas atmosphere. When a solid metal reacts with an acid compound, it is desirable to increase the specific surface area of the metal in order to improve the reaction efficiency.

To this end, the metal may be first cooled at -200 ° C to -205 ° C using liquid nitrogen, and then physically pulverized when the tensile strength of the metal is lowered due to the low elasticity of the metal.

In the case of physically grinding, a mixer, a ball mill, etc. may be used, but is not limited thereto. While grinding in an inert gas atmosphere such as nitrogen, helium, or argon for 5 minutes to 24 hours, it is possible to prevent the combination of oxygen and water vapor, that is, to prevent metal oxidation.

At this time, it is preferable to pulverize the metal to a micrometer size in order to increase the specific surface area of the metal and improve the reaction efficiency with the acid compound. The smaller the average particle diameter of the metal particles, the more efficiently the antioxidant effect can be displayed. Accordingly, the average particle diameter of the metal may be 1 to 50 μm. When the average particle diameter of the metal particles exceeds 50 μm, the antioxidant effect may be insufficient.

A metal particle having a coating film and a metal particle or an anion bonded to each other may be prepared by using the pulverized metal particle.

A coating film may be formed by mixing the pulverized metal particles with one or more of vegetable waxes, vegetable oils, and biodegradable polymers.

In order to prevent oxidation of the pulverized metal particles, a coating film may be formed on the surface of the metal particles using at least one of waxes, oils, and polymers in which hydroxyl groups (OH) do not easily fall off and do not have moisture.

Here, the coating film has an extremely thin thickness like a thin film, and may be formed by mixing and stirring at 24 to 50 ° C. The thickness of the coating film may be approximately 0.01 to 1 nm, preferably 0.01 to 0.5 nm.

Metal particles coated with one or more of vegetable waxes, vegetable oils, and biodegradable polymers will be harmless to the human body.

These coating components may be mixed in an amount of 10 to 50 parts by weight based on 100 parts by weight of the metal particles. By mixing 10 to 50 parts by weight, coating can be smoothly performed on the surface of the metal particles.

Subsequently, by preparing a composition by mixing the coated metal particles, the metal particles, and the acid compound, the composition may include hydrogen generated while mixing the metal particles and the acid compound. When magnesium as a metal particle reacts with acetic acid as an acid compound, the anion moiety separated from the acid compound is combined with magnesium to form magnesium acetate as the metal compound and at the same time generate hydrogen gas.

The composition may include metal particles on which a coating film is formed, and may include metal particles or metal particles to which anions are bonded. Further, the coating film may include hydrogen occluded in the metal particle formed thereon, hydrogen occluded in the metal particle, hydrogen occluded in the metal particle to which anion is bonded, and the like.

In this step, 0.1 to 100 g of metal particles having a coating film, 0.1 to 100 g of metal particles, and 0.1 to 100 g of an acid compound may be mixed, but is not limited thereto.

In particular, since it takes a long time to ionize in a weak acid, hydrogen gas can be generated as slowly as possible and a maximum amount of hydrogen gas can be maintained in the composition.

In order for the reaction to proceed in a weak acid, 0.1 to 10 g of an acid compound may be mixed, and the concentration of the acid compound may be 5 to 60%, specifically 10 to 40%, but is not limited thereto.

As described above, the specific examples of the pharmaceutical composition for preventing or treating metabolic diseases and skin diseases are as follows.

1. Characteristics of patients with atopic dermatitis

As shown in Table 1, 12 atopic dermatitis patients were recruited.

And, as shown in Table 2, the main reaction allergy test was performed on patients with atopic dermatitis.

[Table 1]

[Table 2]

2. Preparation of pharmaceutical compositions for preventing or treating metabolic diseases and skin diseases

1) Magnesium metal was cooled at -200 ° C using a mixer and then pulverized in a nitrogen atmosphere for 5 minutes to prepare magnesium particles having a size of 40 to 50 μm.

Subsequently, vegetable oil was prepared by mixing olive oil, avocado oil, almond oil, apricot seed oil, evening primrose oil, jojoba oil, and rosehip oil in equal proportions.

With respect to 100 parts by weight of the magnesium particles, after mixing 50 parts by weight of the vegetable oil at 30 ° C., magnesium particles having a coating film were prepared. And the pulverized magnesium particles were also prepared together.

A first composition in which hydrogen is stored in magnesium was prepared by reacting 100 g of magnesium particles and 50 g of magnesium particles having a coating film with 10 g of acetic acid.

At this time, the dissolved concentration of hydrogen generated was 10 ppm (v/v).

The evaluation results of FIGS. 1 to 7 using the first composition were described.

2) A second composition was prepared under the same conditions as the method for preparing the first composition, except that 10 parts by weight of vegetable oil was mixed.

3) The third composition was prepared under the same conditions as the preparation method of the first composition, except that 1 g of acetic acid was reacted.

4) A fourth composition was prepared under the same conditions as in the preparation method of the first composition, except that 1 g of an acid obtained by mixing succinic acid and glutaric acid in a 1:1 ratio was reacted instead of acetic acid.

5) After preparing herbal medicines mixed with japonica, cnidium, licorice, yongnoe, and peony in equal proportions, The fifth composition was prepared under the same conditions as the preparation method of the first composition, except that 0.1 g of the herbal medicine was mixed together in the step of mixing magnesium particles and acetic acid during the preparation process of the first composition.

6) Arborvitae, mulberry leaf, golden, yellow lotus, yellow white, gardenia, yeonkyo, gosam, astragalus, and mint are prepared in equal proportions, and then, in the step of mixing magnesium particles and acetic acid during the manufacturing process of the first composition, the above The sixth composition was prepared under the same conditions as the manufacturing method of the first composition, except that 10 g of herbal medicine was mixed together.

3. Metabolic disease, skin disease improvement and stability evaluation

1 and 2 are photographs showing skin conditions before (left) and after (right) applying the pharmaceutical composition for prevention or treatment according to the present invention to a skin disease site.

Referring to Figures 1 and 2, the atopic dermatitis was improved in all patients who applied the hydrogen-dissolved composition of the present invention, and the reddened symptoms almost disappeared.

Accordingly, it was confirmed that skin diseases are improved by the composition of the present invention.

Figure 3 is a result showing the itching improvement (a), erythema improvement (b), inflammation improvement (c), and healer satisfaction (d) after applying the pharmaceutical composition for prevention or treatment according to the present invention to the skin.

In FIG. 3 , the higher the itch index score, the erythema index score, the inflammation index score, and the healer satisfaction index score, the higher the improvement.

Referring to FIG. 3, when the hydrogen-dissolved composition of the present invention was applied to the skin periodically from August 4 to September 28 once a day, itching, erythema (redness), and inflammation were improved. seemed And the satisfaction of the healers also showed a fairly high result.

Accordingly, it was confirmed that skin diseases such as itching, erythema, and inflammation are improved by the composition of the present invention.

Figure 4 is a result showing pore size reduction (a), elasticity improvement (b), skin roughness improvement (c), wrinkle improvement (d) after applying the pharmaceutical composition for prevention or treatment according to the present invention to the skin.

In FIG. 4 , the pore size index, the skin roughness index, and the wrinkle index mean that they are improved as they are lower than the median values. The elasticity index means that it improves as it is higher than the median value.

As a result of skin measurement, the pore size was reduced, elasticity was improved, and skin roughness and wrinkles were improved.

Figure 5 is a result showing the weight gain inhibitory effect after oral administration of the pharmaceutical composition for prevention or treatment according to the present invention to rats.

The composition of the high-fat diet (HFD) for inducing obesity and hyperlipidemia is shown in Table 3.

[Table 3]

In order to induce obesity in rats in Figure 5, by feeding a high-fat diet (HFD) for 4 weeks, obesity and hyperlipidemia were induced.

The experimental agent (composition) and HFD administration to the rats were continued to drink from 1 week, 2 weeks or 3 weeks until the end of the experiment. As a positive control group, fenofibrate (2 mg per rat) was orally administered once a day as a lipid-lowering agent (treatment for hyperlipidemia).

The body weight of rats fed HFD for 4 weeks showed a gradual increase. On the other hand, the body weight of the rats that consumed the HFD and the experimental agent (composition) showed a tendency to decrease relatively.

In particular, the rats fed the experimental agent (composition) for 3 weeks showed almost the same effect as the rats fed the lipid-lowering agent.

Accordingly, it was confirmed that when the experimental agent (composition) of the present invention was ingested, the weight gain inhibitory effect, the anti-obesity effect, and the hyperlipidemia inhibitory effect appeared.

6 and 7 are toxicity test results showing the safety after long-term oral administration of the pharmaceutical composition for prevention or treatment according to the present invention to rats.

Figure 6 is a graph showing the effect on the weight of each organ when the experimental agent (composition) of the present invention is administered to rats for a long time. Referring to Figure 6, it can be seen that the test agent (composition) of the present invention is administered to rats for a long time without any effect on the weight of the liver, spleen, lung, and kidney.

7 is a graph showing long-term liver toxicity and kidney toxicity test results when the experimental agent (composition) of the present invention is administered to rats for a long period of time. Referring to FIG. 7, no toxicity was observed in rats that ingested the experimental agent (composition) of the present invention for 1 to 3 weeks.

Accordingly, it can be seen that the experimental agent (composition) of the present invention is safe to the body without toxicity even after long-term administration.

In addition, the second to sixth compositions also showed the same or similar results as the metabolic disease and skin disease improvement and stability evaluation results using the first composition.

Therefore, the composition of the present invention can be used for the prevention or treatment of metabolic diseases such as atopy, psoriasis and eczema, one or more skin diseases, hyperlipidemia (hyperlipidemia), and obesity.

As described above, the present invention has been described with reference to the drawings illustrated, but the present invention is not limited by the embodiments and drawings disclosed herein, and various modifications are made by those skilled in the art within the scope of the technical idea of the present invention. It is obvious that variations can be made. In addition, although the operational effects according to the configuration of the present invention have not been explicitly described and described while describing the embodiments of the present invention, it is natural that the effects predictable by the corresponding configuration should also be recognized.

Claims (5)

As a pharmaceutical composition for the prevention or treatment of metabolic diseases and skin diseases,
metal compounds; and
Including; hydrogen occluded in the metal compound,
The metal compound
It includes metal particles having a coating film formed thereon and metal particles or metal particles to which anions are bonded,
The skin disease is one or more of atopy, psoriasis and eczema
A pharmaceutical composition for preventing or treating metabolic diseases and skin diseases.
According to claim 1,
Angelica, Jacho, Cnidium, Swallow, Arborvitae, Mulberry leaf, Licorice, Golden, Yellow lotus, Yellow white, Gardenia, Yeongyo, Gosam, Astragalus, Peppermint, Yongnoe and Peony
A pharmaceutical composition for preventing or treating metabolic diseases and skin diseases.
According to claim 1,
The metal includes magnesium
A pharmaceutical composition for preventing or treating metabolic diseases and skin diseases.
According to claim 1,
The dissolved concentration of hydrogen is 0.01 ~ 30ppm (v / v)
A pharmaceutical composition for preventing or treating metabolic diseases and skin diseases.
According to claim 1,
The coating film includes at least one of vegetable waxes, vegetable oils, and biodegradable polymers.
A pharmaceutical composition for preventing or treating metabolic diseases and skin diseases.

Images